Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...

Champions Oncology, Inc.’s CSBR share price has surged by 7.56%, which has investors questioning if this is right time to ...

GE HealthCare Technologies, Inc. GEHC is well-poised for growth in the coming quarters, courtesy of its continued focus on ...

AbbVie (ABBV) came out with quarterly earnings of $2.46 per share, beating the Zacks Consensus Estimate of $2.39 per share. This compares to earnings of $2.31 per share a year ago. These figures are ...

Learn more about whether Ardagh Metal Packaging S.A. or Sealed Air Corporation is a better investment based on AAII's A+ ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

A report from industry trade group Pharmaceutical Research and Manufacturers of America (PhRMA), conducted by Ernst & Young, ...

AbbVie took a little shot at the Trump administration’s trade policy, as the drugmaker said Friday that rather than tariffs, ...

The United States has a $115.5 billion trade deficit in pharmaceutical products, which the Trump administration has suggested ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

For 2025, AbbVie forecast adjusted earnings per share at between $12.09 to $12.29, compared with earlier guidance in the range of $11.99 to $12.19. It noted that the current guidance is based on the ...

In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research, published ...